NASDAQ: KA - Kineta, Inc.

Yield per half year: -18.63%
Sector: Healthcare

Share chart Kineta, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.

more details
It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.0597
EV/EBITDA -1.78
IPO date 2016-02-11
ISIN US49461C1027
Industry Biotechnology
P/BV 1.89
P/S 23.63
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.005
Див.доход ао 0
Дивиденд ао 10.01
Сайт https://kinetabio.com
Цена ао 0.5521
Число акций ао 0.01105 млрд
Change price per day: 0% (0.4801)
Change price per week: 0% (0.4801)
Change price per month: 0% (0.4801)
Change price per 3 month: -14.27% (0.56)
Change price per half year: -18.63% (0.59)
Change price per year: -86.77% (3.63)
Change price per 3 year: -85.09% (3.22)
Change price per 5 year: -74.6% (1.89)
Change price per 10 year: 0% (0.4801)
Change price per year to date: 0% (0.4801)
All parameters

Underestimation

Title Value Grade
P/S 8.12 1
P/BV 14.45 1
P/E 0 0
EV/EBITDA -2.52 0
Total: 4

Efficiency

Title Value Grade
ROA, % -137.14 0
ROE, % -487.85 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.5 5
Total: 2.35

Debt

Title Value Grade
Debt/EBITDA -0.0838 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 8.84 2
Yield Ebitda, % -73.68 0
Yield EPS, % -99.21 0
Total: 0.4
More

Institutions Volume Share, %
Armistice Capital, LLC 825792 7.53
Vanguard Group Inc 151380 1.38
FMR, LLC 123719 1.13
Geode Capital Management, LLC 50584 0.46
Northern Trust Corporation 36880 0.34
Stifel Financial Corporation 21853 0.2
Financial Advocates Investment Management 21744 0.2
Blackrock Inc. 19957 0.18
Renaissance Technologies, LLC 19044 0.17
ELEMENT POINTE ADVISORS, LLC 17696 0.16



Head Job title Payment Year of birth
Mr. Craig W. Philips President & Secretary 541.67k 1961 (64 years)
Ms. Pauline Kenny Esq., J.D. Advisor 349.72k 1974 (51 year)
Mr. Keith A. Baker Chief Financial Officer 485.75k 1967 (58 years)
Dr. Thierry Guillaudeux Ph.D. Chief Scientific Officer N/A 1968 (57 years)
Mr. Gary Gentges Executive Vice President of Corporate Development

Address: United States, Seattle. WA, 219 Terry Ave. N - open in Google maps, open in Yandex maps
Website: https://kinetabio.com